Homology Medicines Inc. Stock News

The FDA has placed a clinical hold on Homology Medicines Inc''s (NASDAQ: FIXX ) pheNIX gene therapy trial of HMI-102 from the FDA. An official clinical hold letter is expected within 30 days. The reason for the clinical hold is the observations of elevated liver function tests. Thus, there is a need to modify risk mitigation measures in Full story available on Benzinga.com

The FDA has placed a clinical hold on Homology Medicines Inc's (NASDAQ: FIXX) pheNIX gene therapy trial of HMI-102 from the FDA. An official clinical hold letter is expected within 30 days.

Homology Medicines (FIXX) has lost ~35% in the post-market after the genetic medicines company announced that the U.S

London-listed cell and gene therapy Oxford Biomedica Plc (OTC: OXBDF ) said it would form a viral vector manufacturing business with Homology Medicines Inc (NASDAQ: FIXX ). Oxford Biomedica Solutions'' Adeno-Associated Virus (AAV) Manufacturing and Innovation Business will be led by Tim Kelly as CEO and Chair … Full story available on Benzinga.com

Eoneren/E+ via Getty Images Oxford Biomedica (OTCPK:OXBDF) and Homology Medicines (NASDAQ:FIXX) have agreed to establish a high-performing, full scope Adeno-Associated Virus (AAV)

London-listed cell and gene therapy Oxford Biomedica Plc OXBDF said it would form a viral vector manufacturing business with Homology Medicines Inc FIXX. [ALERT[ Matt Maley just released his lates

Homology Medicines Inc (FIXX) shares closed today at 0.3% above its 52 week low of $3.48, giving the company a market cap of $199M. The stock is currently down 4.1% year-to-date, down 72.7% over the past 12 months, and down 81.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 39.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 27.9% The company's stock price performance over the past 12 months lags the peer average by 520.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Homology Medicines Inc (FIXX) shares closed today at 1.9% above its 52 week low of $3.61, giving the company a market cap of $213M. The stock is currently down 67.0% year-to-date, down 67.7% over the past 12 months, and down 80.0% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 50.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 985.0% The company's stock price performance over the past 12 months lags the peer average by 797.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Analysts expect Homology Medicines, Inc. (NASDAQ:FIXX) to announce earnings of ($0.58) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Homology Medicines earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.67). Homology Medicines posted earnings per share []

Wall Street analysts expect that Homology Medicines, Inc. (NASDAQ:FIXX) will post sales of $750,000.00 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Homology Medicines earnings, with estimates ranging from $500,000.00 to $1.00 million. Homology Medicines posted sales of $980,000.00 in the same quarter last year, which suggests a negative []

Los Angeles, USA, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight There are approximately 15+ key companies developing the Phenylketonuria therapies. In the upcoming years, many new products such as CNSA-001/PTC923 (PTC Therapeutics), HMI-102 (Homology Medicines), and SYNB1618 (Synlogic) are also expected to enter the Phenylketonuria market. PTC-923 is expected to be the most promising drug among all the upcoming therapies. DelveInsight''s " Phenylketonuria Pipeline Insight " report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Phenylketonuria pipeline landscapes. It comprises Phenylketonuria pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Phenylketonuria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Phenylketonuria pipeline products. Some of the key takeaways from the Phenylketonuria Pipeline Report Major companies such as Synlogic, Homology Medicines, PTC therapeutics, Rubius Therapeutics, NestlÃ, BioMarin, SOM Biotech, Evox Therapeutics, Moderna Therapeutics, Orpharma, Generation Bio, Erydel, Janana therapeutics, American gene technologies, Applied Pharma Research and others are developing potential drug candidates to improve the Phenylketonuria treatment scenario.

Homology Medicines Inc. (NASDAQ:FIXX) concluded the trading at $4.51 on Friday, December 03 with a fall of -7.01% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $4.85 and 5Y monthly beta was reading -0.42 with its price kept floating in the Homology Medicines Inc. (FIXX) Offers An Excellent Investment Opportunity At Current Levels Read More »

Brokerages expect that Homology Medicines, Inc. (NASDAQ:FIXX) will post earnings of ($0.58) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Homology Medicines earnings, with estimates ranging from ($0.67) to ($0.51). Homology Medicines reported earnings per share of ($0.62) during the same quarter last year, which suggests a []

Analysts forecast that Homology Medicines, Inc. (NASDAQ:FIXX) will announce earnings per share (EPS) of ($0.58) for the current quarter, according to Zacks. Two analysts have issued estimates for Homology Medicines earnings, with the lowest EPS estimate coming in at ($0.67) and the highest estimate coming in at ($0.51). Homology Medicines reported earnings of ($0.62) per []

State Street Corp grew its holdings in shares of Homology Medicines, Inc. (NASDAQ:FIXX) by 5.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 718,260 shares of the companys stock after acquiring an additional 34,900 shares during the quarter. State Street [] The post State Street Corp Acquires 34,900 Shares of Homology Medicines, Inc. (NASDAQ:FIXX) appeared first on ETF Daily News .